Clinical characteristics of high-risk patients with early-stage NKTCL before and after PSM stratification by treatment
| . | RT + CT . | RT alone . | . | RT + CT . | CT + RT . | . | RT alone . | CT + RT . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . |
| Before match | |||||||||
| Total | 155 | 163 | 155 | 509 | 163 | 509 | |||
| Gender, male | 111 (71.6) | 113 (69.3) | .655 | 111 (71.6) | 363 (71.3) | .943 | 113 (69.3) | 363 (71.3) | .626 |
| Age, >60 y | 20 (12.9) | 51 (31.3) | <.001 | 20 (12.9) | 75 (14.7) | .569 | 51 (31.3) | 75 (14.7) | <.001 |
| B symptoms | 69 (44.5) | 43 (26.4) | .001 | 69 (44.5) | 240 (47.2) | .565 | 43 (26.4) | 240 (47.2) | <.001 |
| Elevated LDH | 59 (38.1) | 58 (35.6) | .646 | 59 (38.1) | 220 (43.2) | .255 | 58 (35.6) | 220 (43.2) | .085 |
| ECOG ≥2 | 12 (7.7) | 8 (4.9) | .298 | 12 (7.7) | 30 (5.9) | .408 | 8 (4.9) | 30 (5.9) | .635 |
| UADT | 155 (100) | 163 (100) | 1.000 | 155 (100) | 506 (99.4) | 1.000 | 163 (100) | 506 (99.4) | 1.000 |
| Stage II | 40 (25.8) | 42 (25.8) | .994 | 40 (25.8) | 183 (36.0) | .019 | 42 (25.8) | 183 (36.0) | .016 |
| PTI | 114 (73.5) | 100 (61.3) | .020 | 114 (73.5) | 371 (72.9) | .871 | 100 (61.3) | 371 (72.9) | .005 |
| After match | |||||||||
| Total | 119 | 119 | 151 | 151 | 140 | 140 | |||
| Gender, male | 86 (72.3) | 80 (67.2) | .397 | 109 (72.2) | 114 (75.5) | .513 | 98 (70.0) | 98 (70.0) | 1.000 |
| Age, >60 y | 18 (15.1) | 18 (15.1) | 1.000 | 18 (11.9) | 18 (11.9) | 1.000 | 30 (21.4) | 27 (19.3) | .656 |
| B symptoms | 48 (40.3) | 31 (26.1) | .019 | 66 (43.7) | 66 (43.7) | 1.000 | 40 (28.6) | 37 (26.4) | .688 |
| Elevated LDH | 43 (36.1) | 43 (36.1) | 1.000 | 55 (36.4) | 57 (36.4) | 1.000 | 52 (37.1) | 52 (37.1) | 1.000 |
| ECOG ≥2 | 5 (4.2) | 5 (4.2) | 1.000 | 8 (5.3) | 8 (5.3) | 1.000 | 4 (2.9) | 4 (2.9) | 1.000 |
| UADT | 119 (100) | 119 (100) | 1.000 | 151 (100) | 151 (100) | 1.000 | 140 (100) | 140 (100) | 1.000 |
| Stage II | 28 (23.5) | 28 (23.5) | 1.000 | 39 (25.5) | 39 (25.5) | 1.000 | 40 (28.6) | 40 (28.6) | 1.000 |
| PTI | 84 (70.6) | 84 (70.6) | 1.000 | 111 (73.5) | 111 (73.5) | 1.000 | 99 (70.7) | 99 (70.7) | 1.000 |
| . | RT + CT . | RT alone . | . | RT + CT . | CT + RT . | . | RT alone . | CT + RT . | . |
|---|---|---|---|---|---|---|---|---|---|
| . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . |
| Before match | |||||||||
| Total | 155 | 163 | 155 | 509 | 163 | 509 | |||
| Gender, male | 111 (71.6) | 113 (69.3) | .655 | 111 (71.6) | 363 (71.3) | .943 | 113 (69.3) | 363 (71.3) | .626 |
| Age, >60 y | 20 (12.9) | 51 (31.3) | <.001 | 20 (12.9) | 75 (14.7) | .569 | 51 (31.3) | 75 (14.7) | <.001 |
| B symptoms | 69 (44.5) | 43 (26.4) | .001 | 69 (44.5) | 240 (47.2) | .565 | 43 (26.4) | 240 (47.2) | <.001 |
| Elevated LDH | 59 (38.1) | 58 (35.6) | .646 | 59 (38.1) | 220 (43.2) | .255 | 58 (35.6) | 220 (43.2) | .085 |
| ECOG ≥2 | 12 (7.7) | 8 (4.9) | .298 | 12 (7.7) | 30 (5.9) | .408 | 8 (4.9) | 30 (5.9) | .635 |
| UADT | 155 (100) | 163 (100) | 1.000 | 155 (100) | 506 (99.4) | 1.000 | 163 (100) | 506 (99.4) | 1.000 |
| Stage II | 40 (25.8) | 42 (25.8) | .994 | 40 (25.8) | 183 (36.0) | .019 | 42 (25.8) | 183 (36.0) | .016 |
| PTI | 114 (73.5) | 100 (61.3) | .020 | 114 (73.5) | 371 (72.9) | .871 | 100 (61.3) | 371 (72.9) | .005 |
| After match | |||||||||
| Total | 119 | 119 | 151 | 151 | 140 | 140 | |||
| Gender, male | 86 (72.3) | 80 (67.2) | .397 | 109 (72.2) | 114 (75.5) | .513 | 98 (70.0) | 98 (70.0) | 1.000 |
| Age, >60 y | 18 (15.1) | 18 (15.1) | 1.000 | 18 (11.9) | 18 (11.9) | 1.000 | 30 (21.4) | 27 (19.3) | .656 |
| B symptoms | 48 (40.3) | 31 (26.1) | .019 | 66 (43.7) | 66 (43.7) | 1.000 | 40 (28.6) | 37 (26.4) | .688 |
| Elevated LDH | 43 (36.1) | 43 (36.1) | 1.000 | 55 (36.4) | 57 (36.4) | 1.000 | 52 (37.1) | 52 (37.1) | 1.000 |
| ECOG ≥2 | 5 (4.2) | 5 (4.2) | 1.000 | 8 (5.3) | 8 (5.3) | 1.000 | 4 (2.9) | 4 (2.9) | 1.000 |
| UADT | 119 (100) | 119 (100) | 1.000 | 151 (100) | 151 (100) | 1.000 | 140 (100) | 140 (100) | 1.000 |
| Stage II | 28 (23.5) | 28 (23.5) | 1.000 | 39 (25.5) | 39 (25.5) | 1.000 | 40 (28.6) | 40 (28.6) | 1.000 |
| PTI | 84 (70.6) | 84 (70.6) | 1.000 | 111 (73.5) | 111 (73.5) | 1.000 | 99 (70.7) | 99 (70.7) | 1.000 |